United States Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)*

Atea Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 (Title of Class of Securities)

04683R106 (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☐ Rule 13d-1(c)

 \boxtimes

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

00011	110.010	0011	ochedule 15G	1 450 1 01				
1	1 Names of Reporting Persons							
	JPM P	artn	ners LLC					
2	2 Check the Appropriate Box if a Member of a Group							
	(a) □ (b) □							
3	SEC Use Only							
4	Citizenship or Place of Organization							
	Delaware							
		5	Sole Voting Power					
Number of			0					
Shares		6	Shared Voting Power					
Beneficially Owned by			5,925,000					
Each		7	Sole Dispositive Power					
Reporting Person			0					
With		8	Shared Dispositive Power					
			5,925,000					
9	Aggreg	ate A	Amount Beneficially Owned by Each Reporting Person					
	5,925,000							
10								
	Not Applicable							
11								
	7.2%							
12	2 Type of Reporting Person							
	OO (Limited Liability Company)							

00011	1.0.0.0	0011	Too Schedule 150	1 480 2 01				
1	Names	of R	Reporting Persons					
	Jean-P	ierr	re Sommadossi					
2	Check the Appropriate Box if a Member of a Group							
	(a)							
3	SEC Use Only							
4	Citizenship or Place of Organization							
	United States							
		5	Sole Voting Power					
Number of Shares			1,174,999					
		6	Shared Voting Power					
Beneficially Owned by			5,925,000					
Each		7	Sole Dispositive Power					
Reporting Person With			1,174,999					
		8	Shared Dispositive Power					
			5,925,000					
9								
	7,099,999							
10	Check	if the	e Aggregate Amount in Row (9) Excludes Certain Shares					
	Not Applicable							
11			Class Represented by Amount in Row 9					
	8.4%							
12		Rej	porting Person					
	IN							
	114							

ITEM 1. (a) Name of Issuer:

Atea Pharmaceuticals, Inc. (the "Issuer").

(b) Address of Issuer's Principal Executive Offices:

125 Summer Street, Boston, MA 02110.

ITEM 2. (a) Name of Person Filing:

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

JPM Partners LLC; and Jean-Pierre Sommadossi

(b) Address or Principal Business Office:

The business address of JPM Partners LLC is 2 Avery Street #21E, Boston, MA 02111.

The business address of Jean-Pierre Sommadossi is 125 Summer Street, Boston, MA 02110.

(c) Citizenship:

JPM Partners LLC is a Delaware limited liability company. Dr. Sommadossi is a citizen of the United States.

(d) Title of Class of Securities:

Common stock, par value \$0.001 per share ("Common Stock").

(e) CUSIP Number:

04683R106

ITEM 3.

Not applicable.

ITEM 4. Ownership.

The ownership information below represents beneficial ownership of shares of Common Stock as of December 31, 2021, based upon 83,102,730 shares of Common Stock outstanding as of November 10, 2021, based on the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2021.

(a-c)

CUSIP No. 04683R106	Schedule 13G					Page 4 of 6	
Reporting Person	Amount beneficially owned	Percent	Sole power to vote or to direct the vote:	Shared power to vote or to direct the vote:	Sole power to dispose or to direct the disposition of:	Shared power to dispose or to direct the disposition of:	
JPM Partners LLC	5,925,000	7.2%	0	5,925,000	0	5,925,000	
Jean-Pierre Sommadossi	7,099,999	8.4%	1,174,999	5,925,000	1,174,999	5,925,000	

JPM Partners LLC is the record holder of 5,925,000 shares of Common Stock. Dr. Sommadossi is the manager of JPM Partners LLC and may be deemed to share beneficial ownership of the securities held by JPM Partner LLC. In addition, Dr. Sommadossi beneficially owns 1,174,999 shares of Common Stock subject to stock options that are currently exercisable or will become exercisable within 60 days of December 31, 2021.

ITEM 5. Ownership of Five Percent or Less of a Class.

Not applicable.

ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

ITEM 8. Identification and Classification of Members of the Group.

Not applicable.

ITEM 9. Notice of Dissolution of Group.

Not applicable.

ITEM 10. Certification.

Not applicable.

CUSIP No. 04683R106 Schedule 13G Page 5 of 6

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2022

JPM Partners LLC

By: /s/ Jean-Pierre Sommadossi

Name: Jean-Pierre Sommadossi

Title: Manager

Jean-Pierre Sommadossi

/s/ Jean-Pierre Sommadossi

CUSIP No. 04683R106 Schedule 13G Page 6 of 6

LIST OF EXHIBITS

Exhibit No. Description

99 Joint Filing Agreement (previously filed).